• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

chemotherapeutics - Articles and news items

Characterising therapeutic antibodies and ADCs using mass spectrometry

Characterising therapeutic antibodies and ADCs using mass spectrometry

Issue 4 2016 / 24 August 2016 / Ioannis Papayannopoulos, Celldex Therapeutics

Since the 1970s, the advent of biotechnology has resulted in the development and commercialisation of many therapeutic proteins, including antibodies and antibody fragments, for the treatment of human diseases. Examples include antibody treatments for autoimmune diseases (for example, adalimumab [Humira®] for rheumatoid arthritis), cancers (such as trastuzumab [Herceptin®] for breast cancer), degenerative conditions (including ranibizumab [Lucentis®] for macular degeneration), viral and bacterial infections, as well as others. Additionally, antibodies are used as imaging reagents, linked to radionuclides or non-radioactive rare earth metals, and quite extensively employed as reagents in biomedical research, commercial medical tests and clinical laboratory assays (for example, enzyme-linked immunosorbent assay [ELISA])…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +